Finoriq research workspace
X4 Pharmaceuticals, Inc (XFOR) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for X4 Pharmaceuticals, Inc (XFOR).
Company Snapshot
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
- Company
- X4 Pharmaceuticals, Inc (XFOR)
- Ticker
- XFOR
- Market Cap
- $346.6M
- Latest Price
- $3.675
- Industry
- Biotech & Pharma
X4 Pharmaceuticals, Inc (XFOR) Recent Insider Transactions
Recent market insider transaction records indexed for X4 Pharmaceuticals, Inc (XFOR).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Craig Adam RExecutive Chairman | P | Acquired | $249,997 | 2025-10-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.